Haleon Agrees to Sell ChapStick Brand for Up to $510 Million
By Michael Susin
Haleon said that it has agreed to sell ChapStick lip-care brand to Suave Brands Co. for up to $510 million as it seeks to divest from non-core assets and reduce debt.
The consumer-healthcare business--which was spun out of GSK and is partly owned by Pfizer--said on Thursday it will receive cash proceeds of around $430 million, as well as a passive minority interest in the Suave Brands Co.--a portfolio company of private-equity firm Yellow Wood Partners--valued at up to $80 million.
Haleon said proceeds from the sale will be used to pay down debt.
"[ChapStick] is not a core focus for Haleon. Selling the brand allows us to simplify our business and pay down debt more quickly," Chief Executive Brian McNamara said.
The sale is expected to close in the second quarter of 2024.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
January 25, 2024 02:38 ET (07:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth